STAAR/STAA

$46.77

0.92%
-
1D1W1MYTD1YMAX

About STAAR

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Ticker

STAA

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Thomas Frinzi

Employees

1,056

Headquarters

Lake forest, United States

STAAR Metrics

BasicAdvanced
$2.26B
Market cap
107.18
P/E ratio
$0.43
EPS
0.81
Beta
-
Dividend rate
$2.26B
0.80762
$73.13
$26.66
729.82K
5.616
5.076
0.011
0.054
242.143
4.7%
5.91%
5.4%
107.182
7.023
5.864
5.894
13.37%
-46.2%
25.41%
51.87%

What the Analysts think about STAAR

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 9 analysts.
3.23% upside
High $60.00
Low $33.00
$46.77
Current price
$48.28
Average price target

STAAR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.1% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$76.2M
-5.11%
Net income
$7.7M
60.42%
Profit margin
10.1%
69.18%

STAAR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 25.33%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.18
$0.40
$0.30
$0.13
-
Expected
$0.03
$0.19
$0.18
$0.17
$0.04
Surprise
594.52%
107.79%
68.75%
-25.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for STAAR stock?

STAAR (STAA) has a market cap of $2.26B as of April 19, 2024.

What is the P/E ratio for STAAR stock?

The price to earnings (P/E) ratio for STAAR (STAA) stock is 107.18 as of April 19, 2024.

Does STAAR stock pay dividends?

No, STAAR (STAA) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next STAAR dividend payment date?

STAAR (STAA) stock does not pay dividends to its shareholders.

What is the beta indicator for STAAR?

STAAR (STAA) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the STAAR stock price target?

The target price for STAAR (STAA) stock is $48.28, which is 3.23% above the current price of $46.77. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell STAAR stock

Buy or sell STAAR stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing